Related Experiment Videos
Cyclosporine in severe childhood atopic dermatitis: a multicenter study
J Berth-Jones1, A Y Finlay, I Zaki
1Department of Dermatology, Walsgrave Hospital, Coventry, U.K.
Insights
Cyclosporine effectively treated severe atopic dermatitis (AD) in children. This study found cyclosporine safe and well-tolerated for pediatric patients with severe refractory AD, improving quality of life.
Area of Science:
- Pediatric dermatology
- Immunosuppressive therapy
- Atopic dermatitis research
Background:
- Severe atopic dermatitis (AD) presents significant treatment challenges in children.
- Established adult treatments like cyclosporine have not been previously studied in pediatric AD.
Purpose of the Study:
- To evaluate the efficacy of cyclosporine in treating severe, refractory childhood atopic dermatitis.
- To assess the safety and tolerability profile of cyclosporine in pediatric patients with AD.
Main Methods:
- An open-label study treated 27 children (ages 2-16) with cyclosporine (5 mg/kg/day) for 6 weeks.
- Disease activity was monitored using sign scores, visual analogue scales, and quality-of-life questionnaires.
- Efficacy, safety, and tolerability were assessed using standardized scales and event monitoring.
Main Results:
- Significant improvements were observed across all disease activity measures.
- Twenty-two out of twenty-seven children experienced marked improvement or complete clearing of AD.
- Quality of life improved for both affected children and their families, with good to very good tolerability in 25 subjects.
Conclusions:
- Cyclosporine demonstrates potential as an effective short-term treatment for severe childhood atopic dermatitis.
- The drug appears safe and well-tolerated in the pediatric population studied.
- Further investigation into long-term outcomes and optimal dosing may be warranted.
Background:
Severe atopic dermatitis (AD) remains difficult to treat. Cyclosporine is effective in adults but has not previously been investigated in children with AD.
Objective:
The aims were to investigate the efficacy, safety, and tolerability of cyclosporine in severe refractory childhood AD.
Methods:
Subjects 2 to 16 years of age were treated for 6 weeks with cyclosporine, 5 mg/kg per day, in an open study. Disease activity was monitored every 2 weeks by means of sign scores, visual analogue scales for symptoms, and quality-of-life questionnaires. Adverse events were monitored. Efficacy and tolerability were assessed with five-point scales.
Results:
Twenty-seven children were treated. Significant improvements were seen in all measures of disease activity. Twenty-two showed marked improvement or total clearing. Quality of life improved for both the children and their families. Tolerability was considered good or very good in 25 subjects.
Conclusion:
Cyclosporine may offer an effective, safe, and well-tolerated short-term treatment option for children with severe AD.